Evolving approaches in the management of patients with subarachnoid hemorrhage from 2002 to 2022:The impact of clazosentan and treatment modalities on outcomesOA
Evolving approaches in the management of patients with subarachnoid hemorrhage from 2002 to 2022:The impact of clazosentan and treatment modalities on outcomes
Hajime Maeda;Tsuyoshi Izumo;Kazuaki Okamura;Susumu Yamaguchi;Yoichi Morofuji;Takayuki Matsuo
Department of Neurosurgery,Nagasaki University Graduate School of Biomedical Sciences,Nagasaki 852-8501,Japan||Department of Neurosurgery,Nagasaki Rosai Hospital,Nagasaki 857-0134,JapanDepartment of Neurosurgery,Nagasaki University Graduate School of Biomedical Sciences,Nagasaki 852-8501,JapanDepartment of Neurosurgery,Nagasaki University Graduate School of Biomedical Sciences,Nagasaki 852-8501,JapanDepartment of Neurosurgery,Sasebo City General Hospital,Nagasaki 857-8511,JapanDepartment of Neurosurgery,Nagasaki University Graduate School of Biomedical Sciences,Nagasaki 852-8501,JapanDepartment of Neurosurgery,Nagasaki University Graduate School of Biomedical Sciences,Nagasaki 852-8501,Japan
Subarachnoid hemorrhageRebleedingGeneral anesthesiaMortalityPreoperative management
Subarachnoid hemorrhageRebleedingGeneral anesthesiaMortalityPreoperative management
《脑出血(英文)》 2024 (2)
3-9,7
We would like to thank all the members who supported the Nagasaki SAH Registry Study and Editage(www.editage.com)for the English language editing.This study was funded by the Grants-in-Aid for Scientific Research(C)18K08973(to TI)and(C)21K09180(to TI).The funders had no roles in the study design,data collection,and interpretation of results.
评论